P53-EXPRESSION IN NEOPLASMS OF THE UTERINE CORPUS
P53-EXPRESSION IN NEOPLASMS OF THE UTERINE CORPUS
复制标题
DOI：
10.1093/ajcp/98.1.81
复制
发表时间：
1992-07-01
影响因子：
3.5
通讯作者：
ROSE, PG
中科院分区：
文献类型：
--
作者：
BUR, ME;PERLMAN, C;ROSE, PG
已经认识到肿瘤抑制基因的突变可能具有重要的致癌作用。 尽管在各种器官系统的肿瘤中已经报道了p53肿瘤抑制基因的异常，但在子宫体肿瘤中尚未研究过p53表达。 应用抗p53蛋白的单克隆抗体，对56例子宫肿瘤（40例子宫内膜样腺癌，7例浆液性子宫内膜癌，4例苗勒管混合瘤，2例子宫内膜间质肉瘤，1例平滑肌肉瘤，2例平滑肌瘤）和2例正常子宫内膜的冰冻切片进行免疫过氧化物酶染色。 通过光学显微镜检查评价染色;在具有强/弥漫反应性的癌中，通过数字化图像分析进行评价。将腺癌的p53染色与组织学类型、分级、手术分期和临床随访进行统计学比较。 特异性染色仅见于恶性肿瘤细胞核。 良性细胞不染色。 在14例腺癌和2例混合性苗勒管肿瘤中观察到强/弥漫染色。 在14例腺癌中观察到弱/局灶性染色。 浆液性癌强阳性率高于浆液性子宫内膜癌。 染色模式与组织学分级和分期相关。 免疫染色p53的图像分析与腺癌的类型相关，但与测量病例的分级或分期无关。p53在死于腺癌的8名患者中的5名的肿瘤中强烈表达，但在没有疾病证据且最短随访时间为24个月的5名患者中没有p53表达。 此外，12例持续性或复发性疾病患者中有3例显示肿瘤强烈表达p53。 结论：p53蛋白异常表达在子宫恶性肿瘤中较常见。 p53强免疫过氧化物酶染色与浆液性乳头状组织学类型及子宫内膜癌预后不良有关。
It has been recognized that mutations in tumor suppressor genes may have an important oncogenic role. Although abnormalities of the p53 tumor suppressor gene have been reported in tumors from various organ systems, p53 expression has not been studied in neoplasms of the uterine corpus. Using a monoclonal antibody to the p53 product, frozen sections of 56 uterine tumors (40 endometrioid endometrial adenocarcinomas, 7 serous endometrial carcinomas, 4 mixed Mullerian tumors, 2 endometrial stromal sarcomas, 1 leiomyosarcoma, 2 leiomyomas) and 2 normal endometria were stained using the immunoperoxidase technique. Staining was evaluated by light microscopic examination; in carcinomas with strong/diffuse reactivity, evaluation was by digitized image analysis. p53 staining of adenocarcinomas was compared statistically to the histologic type, grade, surgical stage, and clinical follow-up. Specific staining was present in the nucleus of malignant tumor cells only. Benign cells did not stain. Strong/diffuse staining was seen in 14 adenocarcinomas and in 2 mixed Mullerian tumors. Weak/focal staining was observed in 14 adenocarcinomas. Serous carcinomas showed strong positivity more frequently than endometrioid endometrial carcinomas. Staining patterns correlated with histologic grade and stage. Image analysis of immunostained p53 correlated with type of adenocarcinoma, but not with grade or stage in the cases measured. p53 was expressed strongly in tumors of five of eight patients who died of adenocarcinoma but in none of five patients with no evidence of disease and a minimum follow-up of 24 months. In addition, 3 of 12 patients with persistent or recurrent disease showed tumors that strongly expressed p53. It is concluded that abnormal expression of p53 occurs frequently in malignant uterine tumors. Strong immunoperoxidase staining for p53 is associated with serous papillary histologic type and with poor prognosis in endometrial carcinomas.